Short Interest in Definitive Healthcare Corp. (NASDAQ:DH) Expands By 30.0%

Definitive Healthcare Corp. (NASDAQ:DH) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 2,770,000 shares, an increase of 30.0% from the February 13th total of 2,130,000 shares. Currently, 6.8% of the shares of the company are short sold. Based on an average daily volume of 823,600 shares, the short-interest ratio is currently 3.4 days.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its stake in Definitive Healthcare by 20.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company’s stock worth $85,000 after purchasing an additional 3,496 shares in the last quarter. Principal Financial Group Inc. lifted its stake in Definitive Healthcare by 9.7% in the 4th quarter. Principal Financial Group Inc. now owns 43,960 shares of the company’s stock worth $181,000 after purchasing an additional 3,874 shares in the last quarter. Rhumbline Advisers lifted its stake in Definitive Healthcare by 5.2% in the 4th quarter. Rhumbline Advisers now owns 81,316 shares of the company’s stock worth $334,000 after purchasing an additional 4,034 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in Definitive Healthcare by 18.1% in the 4th quarter. Canada Pension Plan Investment Board now owns 29,300 shares of the company’s stock worth $120,000 after purchasing an additional 4,500 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Definitive Healthcare by 6.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 81,358 shares of the company’s stock worth $334,000 after purchasing an additional 4,748 shares in the last quarter. Institutional investors own 98.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on DH shares. Barclays cut their target price on shares of Definitive Healthcare from $4.00 to $3.00 and set an “underweight” rating for the company in a research report on Monday, March 3rd. Needham & Company LLC reaffirmed a “hold” rating on shares of Definitive Healthcare in a research report on Thursday, January 16th. The Goldman Sachs Group cut their target price on shares of Definitive Healthcare from $4.50 to $3.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Finally, Stephens assumed coverage on shares of Definitive Healthcare in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.00 target price for the company. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, Definitive Healthcare presently has an average rating of “Hold” and an average target price of $5.35.

Definitive Healthcare Price Performance

Definitive Healthcare stock traded up $0.05 during mid-day trading on Monday, hitting $2.64. The stock had a trading volume of 495,281 shares, compared to its average volume of 970,633. The firm has a market capitalization of $297.52 million, a P/E ratio of -0.85, a P/E/G ratio of 4.06 and a beta of 1.51. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $4.34 and its 200 day moving average is $4.37. Definitive Healthcare has a one year low of $2.55 and a one year high of $8.35.

Definitive Healthcare (NASDAQ:DH) last issued its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.04). The firm had revenue of $62.29 million during the quarter, compared to the consensus estimate of $60.60 million. Definitive Healthcare had a positive return on equity of 1.76% and a negative net margin of 142.38%. On average, sell-side analysts forecast that Definitive Healthcare will post 0.16 earnings per share for the current fiscal year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.